No Man

Sign in

Join Free
Post RFQ

Siponimod

TypeName: Business Offer

Category:

Offer Date:2019/09/04

Country: United States

Summary: Siponimod is a selective S1P1 and S1P5 agonist with EC50 of 0.39 nM and 0.98 nM, respectively. It has been approved by US FDA for the treatment of patients with active secondary progressive multiple sclerosis (SPMS).
https://www.bocsci.com/siponimod-cas-1230487-00-9-item-463380.html

Description:

OfferId: 5443

Name:Alex Brown

Telphone:

Email:[email protected]